New combo therapy shows promise for tough brain tumors

NCT ID NCT02866747

Completed Disease control Sponsor: Institut Claudius Regaud Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the immunotherapy drug durvalumab to targeted radiation can help people with recurrent glioblastoma, an aggressive brain cancer that has come back after initial treatment. The trial enrolled 108 adults and first checked safety, then randomly assigned patients to receive either radiation alone or radiation plus durvalumab. The main goal was to see if the combination improves overall survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Durvalumab (immunotherapy drug) and hypofractionated stereotactic radiation therapy (targeted radiation)
What this could lead to: If successful, this combination could offer a new treatment option that extends survival for patients with recurrent glioblastoma, a brain cancer with few effective therapies.
What could go wrong: This is an early-phase trial (Phase I/II) with a small number of patients, so results may not apply broadly. Immunotherapy can cause serious side effects, and the added benefit over radiation alone is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOBLASTOMA

Contacts and locations

Locations

Centre Francois Baclesse

Caen, 14 000, France
Centre Georges Francois Leclerc

Dijon, 21 000, France
Centre Paul Strauss

Strasbourg, 67000, France
Hopital Avicenne

Bobigny, 93 000, France
Hopital Pitie Salpetriere

Paris, 75013, France
Institut Claudius Regaud

Toulouse, France
Institut Curie

Saint-Cloud, 92 210, France
Institut Gustave Roussy

Villejuif, 94 800, France
Institut Regional Du Cancer de Montpellier

Montpellier, 34 298, France
Institut de Cancerologie de L'Ouest

Angers, 49055, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.